证券代码：603811 证券简称：诚意药业 公告编号：2023-025 浙江诚意药业股份有限公司 2023 年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 11 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 100,842,247 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 30.8099 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，以现场和网络投票相结合的方式召开，现 场会议由公司董事长颜贻意先生主持。本次股东大会的召集、召开和表决方式符 (一) 股东大会召开的时间：2023 年 09 月 08 日 (二) 股东大会召开的地点：浙江省温州市洞头区化工路 118 号浙江诚意药业 股份有限公司洞头制造部研发大楼会议室 (三) 出席会议 ...

地址：上海市浦东新区银城中路 501 号上海中心大厦 11/12 楼 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于浙江诚意药业股份有限公司 上海市锦天城律师事务所 关于浙江诚意药业股份有限公司 2023 年第一次临时股东大会的 法律意见书 2023 年第一次临时股东大会的 法律意见书 致：浙江诚意药业股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受浙江诚意药业股份有限 公司（以下简称"公司"）委托，就公司召开 2023 年第一次临时股东大会（以下 简称"本次股东大会"）的有关事宜，根据《中华人民共和国公司法》（以下简称 "《公司法》"）《上市公司股东大会规则》等法律、法规、规章和其他规范性文件 以及《浙江诚意药业股份有限公司章程》（以下简称"《公司章程》"）的有关规定， 出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东大会所涉及的相关 ...

股票简称：诚意药业 股票代码：603811 浙江诚意药业股份有限公司 2023 年第一次临时股东大会 会议资料 2023 年 9 月 8 日 1/6 浙江诚意药业股份有限公司 2023 年第一次临时股东大会 会议资料目录 ● 会议议案 | 序号 | 议案名称 | | --- | --- | | 1 | 关于修订公司章程的议案 | 2/6 ● 会议须知 ● 会议议程 浙江诚意药业股份有限公司 2023 年第一次临时股东大会 会议须知 为维护浙江诚意药业股份有限公司（以下简称"公司"）全体股东的合法权益，确 保股东大会的正常秩序和议事效率，保证大会的顺利进行，特制定本会议须知，请出席 股东大会的全体人员遵照执行： 一、参会资格：股权登记日 2023 年 9 月 4 日下午收盘后，在中国证券登记结算有 限责任公司上海分公司登记在册的持有本公司股票的股东。 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，务必请出席 现场大会的股东或股东代表携带相关证件，提前到达会场登记参会资格并签到。未能提 供有效证件办理签到的，不能参加现场表决和发言。除了股东授权代理人、公司董事、 监事、高级管理人员、公司聘请的见证 ...

证券代码：603811 证券简称：诚意药业 公告编号：2023-024 浙江诚意药业股份有限公司 关于2023年半年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江诚意药业股份有限公司（以下简称"公司"）于 2023 年 8 月 25 日上午 09:00-10:00 在上海证券交易所上证路演中心（http://roadshow.sseinfo.com/） 通过网络文字互动方式召开 2023 年半年度业绩说明会。现将有关事项公告如下： 一、业绩说明会召开情况 2023 年 8 月 17 日，公司在上海证券交易所网站（www.sse.com.cn）及指定信 息媒体披露了《浙江诚意药业股份有限公司关于召开 2023 年半年度业绩说明会的 公告》（公告编号：2023-019）。 2023 年 8 月 25 日上午 09:00-10:00，公司总经理赵春建先生、副总经理任秉 钧先生、副总经理厉市生先生、董事会秘书柯泽慧女士、财务总监吕孙战先生、独 立董事陈志刚先生出席了本次业绩说明会。与投资者进行互 ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately ¥320.86 million, a slight increase of 0.85% compared to ¥318.16 million in the same period last year[20]. - Net profit attributable to shareholders of the listed company reached approximately ¥90.60 million, representing a significant increase of 39.48% from ¥64.96 million in the previous year[20]. - The net cash flow from operating activities increased by 50.63% to approximately ¥107.39 million, up from ¥71.29 million in the same period last year[20]. - Basic earnings per share rose to ¥0.28, a 40% increase compared to ¥0.20 in the same period last year[21]. - The weighted average return on net assets increased to 8.06%, up by 1.62 percentage points from 6.44% in the previous year[21]. - The total assets of the company at the end of the reporting period were approximately ¥1.79 billion, an increase of 4.19% from ¥1.72 billion at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company increased by 2.95% to approximately ¥1.12 billion, compared to ¥1.09 billion at the end of the previous year[20]. - The increase in net profit was primarily due to a significant rise in investment income and a reduction in losses from the subsidiary Jiangsu Chengyi[22]. Market Position and Product Development - The company secured over 41% market share for its main product, Glucosamine Hydrochloride Capsules, in nine provinces[28]. - Four new health food products were launched, with plans for multi-channel promotion to drive sales growth[29]. - The company is actively participating in national pharmaceutical bidding, with significant success in securing contracts[28]. - The company has ten new products under research, including L-Carnitine Injection and Voriconazole API, which have been successfully accepted for filing[29]. - The company plans to enhance its product line through ongoing research and potential acquisitions in the oncology and liver protection sectors[30]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of 500 million allocated for potential deals[75]. Operational Efficiency and Management - The company plans to continue focusing on investment opportunities and improving operational efficiency to sustain growth in the future[22]. - The company has implemented comprehensive risk management strategies to ensure sustainable sales growth[28]. - The company’s marketing center in Shanghai aims to build a robust global sales network by recruiting top marketing talent[28]. - Ongoing research and development efforts have led to the introduction of two new technologies that are anticipated to enhance operational efficiency by 10%[76]. - The company is focusing on enhancing its technological capabilities to improve operational efficiency and product offerings[138]. Environmental Compliance and Sustainability - The company maintained compliance with environmental regulations, with no pollution incidents reported during the reporting period[51]. - The company has implemented a combination of clean production and end-of-pipe treatment to enhance environmental protection efforts[56]. - The company has taken measures to reduce carbon emissions, including solar rooftop photovoltaic power generation and smart energy digital management[70]. - The company has established an emergency response plan for environmental incidents in November 2022, which was approved by the local environmental authority[67]. Shareholder and Capital Management - The company did not propose any profit distribution or capital reserve transfer plans for the half-year period[48]. - The company has a commitment to stabilize its stock price for three years following its IPO, with conditions based on stock performance over 20 consecutive trading days[83]. - If the stock price falls below the latest audited net asset value per share, the company and its major shareholders will initiate measures to stabilize the stock price[83]. - The company plans to repurchase shares to stabilize the stock price, subject to legal and regulatory compliance[84]. - Shareholders must approve any share repurchase decision with at least two-thirds of the voting rights at the meeting[84]. Financial Health and Investments - The company reported a significant increase in revenue, achieving a total of 1.5 billion in the first half of 2023, representing a 20% year-over-year growth[75]. - The total assets of the company at the end of the reporting period are 1,087,885,213.00, showing a growth from 986,308,389.00 in the previous year[142]. - The company has allocated 90,599,041.00 for capital reserves, which is a strategic move to strengthen its financial position[139]. - The overall equity of the company increased to 994,681,383 RMB, reflecting strong financial health and investor confidence[153]. Governance and Compliance - The company has established a structured governance framework, including a board of directors and various specialized committees[161]. - The financial statements comply with the disclosure requirements set forth by the China Securities Regulatory Commission[164]. - The company adheres to the Chinese Accounting Standards, ensuring that the financial statements accurately reflect its financial position and operating results[167].

证券代码：603811 证券简称：诚意药业 公告编号：2023-019 浙江诚意药业股份有限公司 关于召开2023年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 会议召开时间：2023 年 08 月 25 日(星期五)上午 09:00-10:00 ● 会议召开网址：上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com/） ● 会议召开方式：上证路演中心网络文字互动方式 ● 投资者可于 2023 年 08 月 18 日(星期五)至 08 月 24 日(星期四)16:00 前登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 office@chengyipharma.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 浙江诚意药业股份有限公司（以下简称"公司"）将于 2023 年 08 月 24 日发布 公司 2023 年半年度报告，为便于广大投资者更全面深 ...

证券代码：603811 证券简称：诚意药业 公告编号：2023-013 浙江诚意药业股份有限公司 关于参加沪市主板生物医药行业上市公司 2022 年年报集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可于 2023 年 05 月 05 日(星期五) 至 05 月 11 日(星期四)16:00 前登 录上证路演中心网站首页，点击"提问预征集"栏目或通过公司邮箱 office@chengyipharma.com 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 浙江诚意药业股份有限公司（以下简称"公司"）已于 2023 年 04 月 26 日发 布 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度的经营 成果、财务状况，同时更加充分地向投资者展示生物医药行业发展情况，公司计 划于 2023 年 05 月 12 日 上午 10:00-11:00 参加沪市主板医药行业上市公司 2022 年年报集体业绩说明会，就投资者关心的问题进行交流。 一、 说明 ...

Financial Performance - The company's operating revenue for 2022 was approximately ¥654.97 million, a decrease of 5.62% compared to ¥693.96 million in 2021[22]. - The net profit attributable to shareholders for 2022 was approximately ¥161.58 million, down 5.39% from ¥170.80 million in 2021[22]. - The net profit after deducting non-recurring gains and losses was approximately ¥139.98 million, a decrease of 10.45% from ¥156.31 million in 2021[22]. - The cash flow from operating activities for 2022 was approximately ¥165.94 million, an increase of 15.65% compared to ¥143.49 million in 2021[22]. - The total assets at the end of 2022 were approximately ¥1.72 billion, an increase of 29.99% from ¥1.32 billion at the end of 2021[22]. - The net assets attributable to shareholders at the end of 2022 were approximately ¥1.09 billion, up 10.30% from ¥986.31 million at the end of 2021[22]. - Basic earnings per share for 2022 were ¥0.69, a decrease of 5.48% from ¥0.73 in 2021[23]. - The weighted average return on equity for 2022 was 15.66%, down 2.8 percentage points from 18.46% in 2021[23]. Revenue and Sales - The decline in operating revenue was primarily due to market factors affecting sales of products such as calming and brain-nourishing agents, diuretics, vitamins, and intermediates[23]. - Domestic sales accounted for CNY 628.46 million, a decline of 4.60%, while international sales fell by 28.53% to CNY 24.79 million[50]. - The company achieved over 41% market share in nine provinces for its main product, Glucosamine Hydrochloride Capsules, after winning a national procurement bid[32]. - The production of joint drugs reached 121,475.70 million units, an increase of 16.97% compared to the previous year, while sales were 120,698.31 million units, up by 15.45%[53]. - The sales of diuretic drugs decreased by 39.30% to 494.40 million units, with a sales volume of 573.92 million units, down by 20.42%[54]. - The company reported a significant decline in sales of sedative and brain-nourishing drugs, with a sales volume drop of 92.55% to 2,707.45 kg[54]. Research and Development - The company has 17 new products under research, with key products like Aspartate and Ornithine approved[33]. - The total R&D expenditure amounted to 44,304,378.52 yuan, representing 6.76% of total revenue, with a year-on-year increase of 11.56% in R&D expenses[62]. - The company is committed to continuous product research and development, focusing on anti-tumor, circulatory system, and liver protection drugs to expand its product line[41]. - The company is focusing on the consistency evaluation of 10 oral solid preparations, with key products like glucosamine hydrochloride capsules approved[102]. - The company has ongoing research projects for various chemical drugs aimed at treating conditions such as osteoarthritis, dehydration from diarrhea, and chronic hepatitis B[82]. Product Development and Innovation - The company launched four new health food products, aiming to drive sales growth through multi-channel promotion[33]. - The company has developed marine biological pharmaceutical products, primarily focusing on glucosamine hydrochloride capsules (Weiergu), with a market share of over 41% in nine provinces and cities after winning the first bid in the national centralized procurement in August 2020[35]. - The company is focusing on developing treatments for respiratory diseases and viral infections, reflecting a strategic alignment with current healthcare needs[82]. - The company has a pipeline of new products, including those targeting severe infections and heart failure, showcasing its commitment to expanding its therapeutic offerings[82]. Market Strategy and Expansion - The company plans to expand its market presence through the introduction of new drugs and technologies, focusing on therapeutic areas such as joint diseases and viral infections[70]. - The company is expanding its production capabilities with the acquisition of Fujian Huakang Pharmaceutical Co., enhancing its supply chain for key products[44]. - The company is focusing on marine pharmaceuticals, leveraging its location in Wenzhou to develop marine-based drugs[44]. - The company is actively involved in the procurement process, with significant volumes for drugs like Torasemide Injection, which had a procurement volume of 3,853,901 units[75]. Corporate Governance and Compliance - The company has established a robust governance structure to ensure compliance with laws and protect shareholder rights, with no reported issues requiring regulatory remediation[108]. - The board of directors operates independently, ensuring no undue influence from the controlling shareholder, maintaining operational autonomy[109]. - The company has implemented strict information disclosure protocols to enhance transparency and prevent insider trading, safeguarding shareholder interests[110]. - The company is committed to continuous improvement in corporate governance and internal control mechanisms to promote sustainable development[110]. Environmental and Social Responsibility - The company is committed to sustainable development and has implemented pollution prevention measures in line with clean production principles[151]. - The company has ongoing projects, including a marine biopharmaceutical manufacturing project with an annual production capacity of 1000 tons of super fish oil EPA[155]. - The company made a total charitable contribution of 300,000 RMB for public welfare projects during the reporting period[162]. - The company has established a feasible emergency response plan for environmental incidents in November 2022, which was approved by the local environmental authority[157]. Shareholder and Executive Management - The total number of shares held by the chairman, Yan Yiyi, remained unchanged at 55,137,200 shares, with a pre-tax compensation of 1.0466 million yuan[113]. - The total number of shares held by director Qiu Kerong decreased by 600,000 shares, ending the year with 1,908,800 shares, with a pre-tax compensation of 420,100 yuan[113]. - The total pre-tax compensation for all executives during the reporting period amounted to 7.8321 million yuan[114]. - The company appointed Zhao Chunjian as the new general manager and made several changes to the executive team, including the appointment of new vice presidents and a financial director[114]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 1.32 billion CNY[120]. - New product launches are expected to contribute an additional 200 million CNY in revenue, with a focus on innovative healthcare solutions[119]. - The company plans to increase its marketing budget by 20% to support brand awareness and customer engagement initiatives[120].

Financial Performance - The company's operating revenue for Q1 2023 was ¥147,830,388.05, representing a decrease of 7.40% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥39,749,555.71, an increase of 37.44% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥38,805,216.40, up by 25.50% compared to the previous year[6]. - The net profit for Q1 2023 was CNY 39,622,334.78, representing a 37% increase compared to CNY 28,958,813.98 in Q1 2022[21]. - Operating profit for Q1 2023 reached CNY 41,796,167.73, up 24% from CNY 33,595,681.95 in the same period last year[21]. - The company reported a total comprehensive income of CNY 39,623,926.08 for Q1 2023, compared to CNY 28,943,664.77 in Q1 2022, indicating a 37% growth[22]. Earnings and Shareholder Returns - Basic and diluted earnings per share were both ¥0.17, representing a growth of 41.67%[6]. - Basic and diluted earnings per share for Q1 2023 were both CNY 0.17, up from CNY 0.12 in Q1 2022[22]. Cash Flow and Liquidity - The net cash flow from operating activities was ¥47,267,096.86, reflecting a 39.42% increase year-on-year[6]. - Cash flow from operating activities showed a net increase of CNY 47,267,096.86, compared to CNY 33,901,895.37 in the previous year, marking a 39% improvement[26]. - Cash and cash equivalents at the end of Q1 2023 totaled CNY 295,962,413.46, a significant increase from CNY 77,856,033.89 at the end of Q1 2022[27]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,815,716,832.96, an increase of 5.62% from the end of the previous year[6]. - Current assets as of March 31, 2023, totaled CNY 508,170,893.23, an increase of 16.4% from CNY 436,837,586.65 at the end of 2022[16]. - Non-current assets amounted to CNY 1,307,545,939.73, up from CNY 1,282,255,938.30 at the end of 2022[17]. - Total liabilities were CNY 685,161,016.86, compared to CNY 628,161,634.93 at the end of 2022, indicating a rise of 9.1%[18]. - Shareholders' equity attributable to the parent company was ¥1,127,636,203.30, up by 3.65% compared to the previous year[6]. - Shareholders' equity as of March 31, 2023, was CNY 1,130,555,816.10, an increase from CNY 1,090,931,890.02 at the end of 2022[18]. Borrowings and Financing - The company experienced a 38.83% increase in cash and cash equivalents, primarily due to increased bank borrowings[9]. - The company reported a significant increase of 126.94% in short-term borrowings, attributed to increased bank loans[9]. - Short-term borrowings increased significantly to CNY 173,602,852.77 from CNY 76,498,172.22 at the end of 2022, marking a rise of 127.5%[17]. - The company raised CNY 190,000,000.00 through borrowings in Q1 2023, compared to CNY 53,649,744.44 in the same period last year, indicating a substantial increase in financing activities[27]. Operating Costs and R&D - Total operating costs for Q1 2023 were CNY 122,646,292.57, down 2.3% from CNY 126,228,137.67 in Q1 2022[20]. - Operating costs included CNY 52,009,448.21 in cost of goods sold, which increased by 12.0% from CNY 46,376,303.16 in the previous year[20]. - Research and development expenses decreased by 30.57%, mainly due to reduced material costs and outsourced R&D expenses[10]. - The company incurred R&D expenses of CNY 8,275,164.89 in Q1 2023, down from CNY 11,918,349.97 in the same quarter last year, reflecting a 30% decrease[21]. Investment Activities - The total cash outflow from investing activities was CNY 29,010,001.14 in Q1 2023, down from CNY 88,883,426.86 in Q1 2022, showing a reduction of 67%[26].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603811 证券简称：诚意药业 浙江诚意药业股份有限公司 2022 年第三季度报告 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 2022 年第三季度报告 单位：元 币种：人民币 | 项目 | 本报告期金额 | 年初至报告期末金额 | 说明 | | --- | --- | --- | --- | | 非流动性资产处置损 | -350,259.42 | -250,288.86 | | | 益 | | | | | 越权审批，或无正式批 | | | | | 准文件，或偶发性的税 | | | | | 收返还、减免 | | | | | 计入当期损益的政府 | | | | | 补助，但与公司正常经 | | | | | ...